Ioannis Parodis

Ioannis Parodis

Adjunct lecturer

Email:
ioannis.parodis@ki.se
Organisation:

MD PhD | Associate Professor

Consultant rheumatologist

Research area: clinical and translational research within the field of inflammation and autoimmunity.

About me

  • 2021 (ongoing) - Coordinator for clinical competencies in the Curriculum Committee of the Medical Programme at the Karolinska Institutet
  • 2020 (ongoing) - Director of studies for the elective courses in the Medical Programme at the Karolinska Institutet
  • 2020 (ongoing) - Member of the Delegation for Education of the Swedish Society of Medicine
  • 2020 (ongoing) - Member of the working group for Interprofessional Learning Environments, Region Stockholm
  • 2019 – 2021 - Deputy Director of Studies for the Internal Medicine course of the Medical Programme at the Karolinska Institutet
  • 2018 (ongoing) - Responsible for the elective course "Acute and chronic inflammation", Karolinska Institutet
  • 2018 (ongoing) - Promoter for Interprofessional Education, Karolinska Institutet
  • 2017 (ongoing) - Convener for the national working group for rheumatology learning outcomes for undergraduates within the frame of the Swedish Society for Rheumatology
  • 2017 (ongoing) - Responsible for the course for Rheumatology residents "Inflammatory systemic diseases", Karolinska Institutet/Karolinska University Hospital
  • 2015 (ongoing) - Responsible for the clinical rotation "Inflammatory diseases" (LINK/ERASMUS), Karolinska Institutet
  • 2015 – 2020 - Responsible for the Rheumatology clinical rotations for undergraduates, Karolinska University Hospital

Research description

The goal of my research is to contribute to improved management and outcomes for people living with systemic lupus erythematosus. We focus on identification of biomarkers that reflect activity and portend flare, response or non-response to therapy, and long-term outcome. We stress on patient-reported health status and patient participation in medical care. We also pursue projects within medical pedagogy; we are currently working on the development of innovative social robotic modalities for the presentation of virtual patient scenarios.

 

Publication list

 

1 Bibliometric results (as of October 9th, 2022)

h-index: 19 (Google scholar)

i10-index: 25 (Google scholar)

Total number of citations: 1313 (see graph below for the yearly distribution; Google scholar)

Total number of publications: 100 (Web of Science)Chart, histogram Description automatically generated

 

 

2 Scientific publications

* Indicates that the publication was included in my doctoral thesis.

# Indicates equal contribution.

! Indicates the ten most important publications.

 

2.1 Original works

  1. Yoshida A, Kim M, Kuwana M, Naveen R, Makol A, Sen P, Lilleker JB, Agarwal V, Kardes S, Day J, Milchert M, Joshi M, Gheita T, Salim B, Velikova T, Edgar Gracia-Ramos A, Parodis I, O'Callaghan AS, Nikiphorou E, Chatterjee T, Tan AL, Nune A, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Group CS. Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey. Rheumatology (Oxford). 2022.
  2. Sen P, R N, Nune A, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, Nikiphorou E, Chatterjee T, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Group CS. COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (Oxford). 2022.
  3. Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, Nikiphorou E, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal V, Aggarwal R, Group CS. COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatology international. 2022;42(1):23-9.
  4. Parodis I, Gomez A, Lindblom J, Chow JW, Doria A, Gatto M. Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. Front Med (Lausanne). 2022;9:852162.
  5. Parodis I, Gomez A, Chow JW, Borg A, Lindblom J, Gatto M. Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab. Front Immunol. 2022;13:796508.
  6. Hernandez-Breijo B, Parodis I, Novella-Navarro M, Martinez-Feito A, Navarro-Compan V, Diaz-Almiron M, Pascual-Salcedo D, Balsa A, Plasencia-Rodriguez C. Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis. J Clin Med. 2022;11(17).
  7. Gil-Vila A, Ravichandran N, Selva-O'Callaghan A, Sen P, Nune A, Gaur PS, Gonzalez RA, Lilleker JB, Joshi M, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, and the CSG. COVID-19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies. Muscle Nerve. 2022;66(4):426-37.
  8. Fazal ZZ, Sen P, Joshi M, Ravichandran N, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Makol A, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Nikiphorou E, Tan AL, Chatterjee T, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Selva-O'Callaghan A, Nune A, Knitza J, Kuwana M, Gutierrez CT, Caballero-Uribe CV, Dey D, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Group CS. COVAD survey 2 long-term outcomes: unmet need and protocol. Rheumatology international. 2022.
  9. Emamikia S, Oon S, Gomez A, Lindblom J, Borg A, Enman Y, Morand E, Grannas D, van Vollenhoven RF, Nikpour M, Parodis I. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022.
  10. Emamikia S, Gentline C, Enman Y, Parodis I. How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study. J Clin Med. 2022;11(7).
  11. Chalmers SA, Ayilam Ramachandran R, Garcia SJ, Der E, Herlitz L, Ampudia J, Chu D, Jordan N, Zhang T, Parodis I, Gunnarsson I, Ding H, Shen N, Petri M, Mok CC, Saxena R, Polu KR, Connelly S, Ng CT, Mohan C, Putterman C. The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses. The Journal of clinical investigation. 2022;132(1).
  12. Samuelsson I, Parodis I, Gunnarsson I, Zickert A, Hofman-Bang C, Wallen H, Svenungsson E. Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case-control study. Lupus Sci Med. 2021;8(1).
  13. Parodis I, Vital EM, Hassan SU, Jonsen A, Bengtsson AA, Eriksson P, Leonard D, Gunnarsson I, Ronnblom L, Sjowall C. De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2021;60(9):4348-54.
  14. Parodis I, Nikpour M. How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. Ann Rheum Dis. 2021;80(7):e119.
  15. Parodis I, Andersson L, Durning SJ, Hege I, Knez J, Kononowicz AA, Lidskog M, Petreski T, Szopa M, Edelbring S. Clinical Reasoning Needs to Be Explicitly Addressed in Health Professions Curricula: Recommendations from a European Consortium. Int J Environ Res Public Health. 2021;18(21).
  16. Lindblom J, Gomez A, Borg A, Emamikia S, Ladakis D, Matilla J, Pehr M, Cobar F, Enman Y, Heintz E, Regardt M, Parodis I. EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(10):4703-16.
  17. Hernandez-Breijo B, Navarro-Compan V, Plasencia-Rodriguez C, Parodis I, Gehin JE, Martinez-Feito A, Novella-Navarro M, Mezcua A, Warren DJ, Nozal P, Pascual-Salcedo D, Balsa A. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors. Sci Rep. 2021;11(1):11632.
  18. Gomez A, Qiu V, Cederlund A, Borg A, Lindblom J, Emamikia S, Enman Y, Lampa J, Parodis I. Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus. Front Med (Lausanne). 2021;8:651249.
  19. Gomez A, Hani Butrus F, Johansson P, Akerstrom E, Soukka S, Emamikia S, Enman Y, Pettersson S, Parodis I. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(3):1260-72.
  20. Borg A, Gomez A, Cederlund A, Cobar F, Qiu V, Lindblom J, Emamikia S, Enman Y, Pettersson S, Parodis I. Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE. Rheumatology (Oxford). 2021;60(9):4205-17.
  21. ! Parodis I, Gokaraju S, Zickert A, Vanarsa K, Zhang T, Habazi D, Botto J, Serdoura Alves C, Giannopoulos P, Larsson A, Svenungsson E, Gunnarsson I, Mohan C. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2020;59(9):2237-49.
  22. ! Parodis I, Akerstrom E, Sjowall C, Sohrabian A, Jonsen A, Gomez A, Frodlund M, Zickert A, Bengtsson AA, Ronnelid J, Gunnarsson I. Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. Int J Mol Sci. 2020;21(10).
  23. ! Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, Houssiau FA, Tamirou F. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford). 2020;59(11):3424-34.
  24. Gomez A, Soukka S, Johansson P, Akerstrom E, Emamikia S, Enman Y, Chatzidionysiou K, Parodis I. Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. J Clin Med. 2020;9(6).
  25. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-23.
  26. ! Sohrabian A#, Parodis I#, Carlstromer-Berthen N, Frodlund M, Jonsen A, Zickert A, Sjowall C, Bengtsson AA, Gunnarsson I, Ronnelid J. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):259.
  27. *! Ramskold D#, Parodis I#, Lakshmikanth T, Sippl N, Khademi M, Chen Y, Zickert A, Mikes J, Achour A, Amara K, Piehl F, Brodin P, Gunnarsson I, Malmstrom V. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine. 2019;40:517-27.
  28. Parodis I, Lopez Benavides AH, Zickert A, Pettersson S, Moller S, Welin Henriksson E, Voss A, Gunnarsson I. The Impact of Belimumab and Rituximab on Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(6):811-21.
  29. Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. Rheumatology (Oxford). 2019;58(12):2170-6.
  30. ! Parodis I#, Emamikia S#, Gomez A, Gentline C, Arkema EV, Chatzidionysiou K, van Vollenhoven RF. Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. The Lancet Rheumatology. 2019;1(3):e163-e73.
  31. Parodis I, Gomez A, Emamikia S, Chatzidionysiou K. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(7):1006-7.
  32. Parodis I, Emamikia S, Gomez A, Gunnarsson I, van Vollenhoven RF, Chatzidionysiou K. Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. Expert Opin Biol Ther. 2019;19(2):157-68.
  33. ! Parodis I, Ding H, Zickert A, Cosson G, Fathima M, Gronwall C, Mohan C, Gunnarsson I. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. PloS one. 2019;14(2):e0212068.
  34. Hernandez-Breijo B, Gomez A, Soukka S, Johansson P, Parodis I. Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Autoimmun Rev. 2019;18(10):102372.
  35. ! Parodis I, Soder F, Faustini F, Kasza Z, Samuelsson I, Zickert A, Svenungsson E, van Vollenhoven RF, Malmstrom V, Wermeling F, Gunnarsson I. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. Lupus. 2018;27(9):1470-8.
  36. Parodis I, Gomez A, Frodlund M, Jonsen A, Zickert A, Sjowall C, Bengtsson AA, Gunnarsson I. Smoking reduces the efficacy of belimumab in mucocutaneous lupus. Expert Opin Biol Ther. 2018;18(8):911-20.
  37. Edelbring S, Parodis I, Lundberg IE. Increasing Reasoning Awareness: Video Analysis of Students' Two-Party Virtual Patient Interactions. JMIR Med Educ. 2018;4(1):e4.
  38. * Parodis I, Ding H, Zickert A, Arnaud L, Larsson A, Svenungsson E, Mohan C, Gunnarsson I. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. Scand J Rheumatol. 2017;46(4):263-72.
  39. *! Parodis I, Sjowall C, Jonsen A, Ramskold D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Ronnelid J, Malmstrom V, Bengtsson AA, Gunnarsson I. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017;16(4):343-51.
  40. Zickert A, Oke V, Parodis I, Svenungsson E, Sundstrom Y, Gunnarsson I. Interferon (IFN)-lambda is a potential mediator in lupus nephritis. Lupus Sci Med. 2016;3(1):e000170.
  41. * Parodis I, Arnaud L, Gerhardsson J, Zickert A, Sundelin B, Malmstrom V, Svenungsson E, Gunnarsson I. Antiphospholipid Antibodies in Lupus Nephritis. PloS one. 2016;11(6):e0158076.
  42. * Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, Malmstrom V, Gunnarsson I. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med. 2015;2(1):e000061.
  43. Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus. 2013;22(4):372-80.

 

2.2 Reviews and book chapters

  1. Palazzo L, Lindblom J, Mohan C, Parodis I. Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature. Journal of Clinical Medicine. 2022;11(19):5759.
  2. Gomez A, Parodis I. Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. Autoimmun Rev. 2022;21(11):103188.
  3. Parodis I, Gatto M, Sjowall C. B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. Front Med (Lausanne). 2022;9:952304.
  4. Lindblom J, Mohan C, Parodis I. Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights. Curr Opin Rheumatol. 2022;34(2):139-49.
  5. Parodis I, Tamirou F, Houssiau FA. Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy? Arch Immunol Ther Exp (Warsz). 2022;70(1):8.
  6. Lindblom J, Mohan C, Parodis I. Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade. Brain Sci. 2022;12(2).
  7. Parodis I, Studenic P. Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver's Seat in Their Disease Monitoring? J Clin Med. 2022;11(2).
  8. Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G, Mosca M. Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21.
  9. Dey M, Parodis I, Nikiphorou E. Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. J Clin Med. 2021;10(16).
  10. Parodis I, Stockfelt M, Sjowall C. B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Front Med (Lausanne). 2020;7:316.
  11. Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med. 2020;7(1):e000389.
  12. ! Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.
  13. Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Curr Vasc Pharmacol. 2020;18(6):549-65.
  14. Parodis I, Dani L, Notarnicola A, Martenhed G, Fernstrom P, Matikas A, Wiklander OPB. G-CSF-induced aortitis: Two cases and review of the literature. Autoimmun Rev. 2019;18(6):615-20.
  15. van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol. 2013;27(3):341-9.

 

 

2.3 Other scientific works

 

  1. Sen P, Lilleker J, Agarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos A, Parodis I, #39, Callaghan A, Nikiphorou E, Tan A, Cavagna L, Saavedra M, Shinjo S, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal R, Gupta L. Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian Journal of Rheumatology. 2022;17(2):188-91.
  2. Sciascia S, Parodis I, Karim MY. Editorial: Clinical, Molecular and Adverse Responses to B-Cell Therapies in Autoimmune Disease. Front Immunol. 2022;13:962088.
  3. Parodis I, Houssiau FA. From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? Ann Rheum Dis. 2022;81(1):15-9.
  4. Stamm T, Parodis I, Studenic P. Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus. The Lancet Rheumatology. 2022;4(3):e157-e9.
  5. Parodis I, Sjöwall C, Weiner M. [Lupus nephritis] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2020; 4
  6. Parodis I. [News about Benlysta] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2019; 3
  7. Parodis I, Dani L, Notarnicola A, Martenhed G, Fernström P, Matikas A, Wiklander O. [Drug-induced aortitis] (Article in Swedish). ReumaBulletinen: Swedish Society for Rheumatology. 2019; 1
  8. Parodis I. Expert view: Refining the use of belimumab in SLE. 2019 Apr; Hospital Healthcare Europe

http://www.hospitalhealthcare.com/editors-pick/expert-view-refining-use-belimumab-patients-sle

  1. Parodis I. [Pharmacological treatment in SLE] (Article in Swedish). Bulletinen: Swedish Rheumatism Association. 2018; 4
  2. Parodis I. Expert view: Ustekinumab for SLE? 2018 Dec; Hospital Healthcare Europe

http://www.hospitalhealthcare.com/editors-pick/expert-view-ustekinumab-sle

  1. Parodis I. Optimising management of systemic lupus erythematosus. Hospital Healthcare Europe. 2018; 190-4

https://hospitalhealthcare.com/latest-issue-2018/optimising-management-of-systemic-lupus-erythematosus/

  1. Parodis I. [Endocardial thrombi in Behçet’s disease] (Article in Swedish). ReumaBulletinen: Swedish Society for Rheumatology. 2017; 7
  2. Parodis I. The latest in lupus, arthritis, and ankylosing spondylitis. Medscape. 2016 Aug.

https://www.medscape.com/viewarticle/867158

  1. Parodis I. From Rome, the latest in Rheumatology. Medscape. 2015 Aug.

https://www.medscape.com/viewarticle/849111

  1. Parodis I, Gunnarsson I. [Lupus nephritis – where do we stand today?] (Article in Swedish). ReumaBulletinen Vetenskap: Swedish Society for Rheumatology. 2014; 6

Teaching portfolio

Current doctoral students

Serving as main supervisor:

  • Shahrzad Kia Komujuni (Karolinska Institutet)
  • Alvaro Gomez Gonzalez (Karolinska Institutet)
  • Julius Lindblom (Karolinska Institutet)
  • Alexander Borg (Karolinska Institutet)

Serving as co-supervisor:

  • Tomas Walhelm (Linköping University)

Education

Associate Professor of Rheumatology: December 2021

Medical specialty (rheumatology): November 2012, Karolinska University Hospital

Medical licensure: 14 August 2006

Medical degree: 2 August 2006, University of Athens, Greece

Doctoral education: 2013–2017

  • Defence: 17 February 2017
  • Title: Systemic lupus erythematosus: Biomarkers and biologics
  • University: Karolinska Institutet
  • Main supervisor: Professor Iva Gunnarsson

Post-doctoral training

  • 2021/2022 Region Stockholm/KI-funded post-doctoral position: “Tailoring patient selection for biological therapy, and optimising surveillance and treatment outcome in systemic lupus erythematosus”
  • 2019 Université catholique de Louvain (Brussels): “Repeat kidney biopsy in lupus nephritis”; Host/supervisor: Professor Frédéric Houssiau

Academic honours, awards and prizes

  • 2020 Amgen and Swedish Society of Rheumatology Award/Stipend
  • 2019 Eli Lilly and Swedish Society of Rheumatology Award/Stipend
  • 2019 Pedagogy award for best supervisor of medical students (internal medicine course, MedS, KI)
  • 2019 Winner of the European Lupus Society Training Bursary Programme (of six)
  • 2018 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Exchange programme; chosen participant (of ten)
  • 2014 Pedagogy award for best supervisor of medical students (internal medicine course, MedS, KI)
  • 2007 Prize for best poster, 13th national scientific meeting for med stud and young physicians, Greece

Links

http://parodislab.com

Documents

CV - Ioannis Parodis (PDF, 191.52 KB)
Publication list (as of October 15th, 2022) (PDF, 159.3 KB)